| Laboratoire Francais Du Fractionnement Et Des Biotechnologies Patent applications |
| Patent application number | Title | Published |
|---|
| 20120039886 | USE OF AN IMMUNOGLOBULIN G (IGG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES FOR TREATING NEONATAL JAUNDICE CAUSED BY MATERNAL-FOETAL INCOMPATIBILITY WITH RESPECT TO THE ABO SYSTEM - An embodiment relates to the use of an immonuglobulin (IgG) concentrate depleted of anti-A (AcaA) and anti-B (AcaB) antibodies for producing a drug intended for treating neonatal jaundice caused by maternal-fetal incompatibility with respect to the ABO system. | 02-16-2012 |
| 20110318332 | IMMUNOGLOBULIN G COMPOSITION - The invention relates to an immunoglobulin G composition comprising mannitol, glycine and a nonionic detergent, in which the immunoglobulin G concentration is 100 g/l±20 g/l. | 12-29-2011 |
| 20090081781 | Synthetic and standardized prion infectuous material, and uses thereof as an injecting inoculum - The invention concerns a novel, synthetic, standardised, soluble, reproducible and easy-to-handle infectious material of the prion type, consisting of a cell lysate or culture supernatant from stable transgenic cells expressing a prion protein PrP and supporting replication of the pathogenic form, PrPsc, of the said Prp. | 03-26-2009 |
| 20090053233 | Cytotoxic Antibody Directed Against Type B Lymphoid Hematopoietic Proliferations - The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of FcγRIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma. | 02-26-2009 |
| 20080207878 | Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins - Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins | 08-28-2008 |
